You know the feeling. An FDA alert lands in your inbox. A wholesaler call comes in. A rep mentions a fill rate drop in passing.
By the time any of those things happen, the window to act strategically has usually closed.
That's the reactive trap, and it's quietly becoming one of the most expensive operational realities in pharmacy today. According to ASHP, more than 216 drug products are in active shortage as of Q4 2025, with three-quarters of them dating back to 2022 or earlier. For pharmacy leaders still relying on official alerts as their primary early warning system, the math simply doesn't work anymore.
The shift that matters isn't just from reactive to proactive. It's from proactive to predictive, and it's redefining what good pharmacy leadership actually looks like.
Most pharmacy teams have gotten very good at managing shortages after the fact. Sourcing alternatives under pressure. Calling reps. Adjusting clinical protocols on the fly. Communicating substitutions to prescribers.
That capability matters. But it's built for a world where shortages were periodic and manageable. That world no longer exists.
The financial toll is significant: drug shortages now cost the U.S. healthcare system an estimated $720 million annually in direct costs, in an industry already operating on thin margins. That figure doesn't capture the secondary expenses accumulating quietly on pharmacy P&Ls: diverted staff time, overtime, emergency procurement fees and the clinical cost of substitutions that may not be therapeutically equivalent.
When a shortage hits and a team scrambles to source an alternative, the replacement product typically costs between 88% and 250% more than what would have been purchased under normal market conditions. In a low-margin business, that's not a rounding error. It's a structural threat.
And it compounds. According to a Vizient drug shortages survey, 41% of outpatient infusion patients experienced a care disruption directly attributable to a drug shortage. Planned medical procedures were disrupted in 32% of cases. The workload required to keep patients protected is enormous, and largely invisible in the data.
As Jessica Daley, PharmD, Founder of Daley Consulting Services and former Chief Pharmacy Officer and Group Vice President of Supply Chain at Premier Inc., put it plainly: "Once you wait, you're too late. And by the time you make a decision, the product is already out of the market."
Drug shortage prediction isn't a single tool or a feed you subscribe to. It's a capability built from four things working in concert.
Early signal detection means monitoring beyond FDA and ASHP shortage lists. It means watching vendor inventory levels, wholesaler fulfillment trends and distribution patterns across the entire supplier network to identify the precursors to a shortage before it's officially declared. That two-month lead time changes everything about how a pharmacy team can respond.
Consolidated data means bringing disparate sources into a single system where they can be analyzed together: vendor feeds, FDA data, internal purchasing history and network-wide purchasing patterns. The challenge today isn't a lack of data. As Daley noted, "This is a massive data dump. There are millions of data points that change on a routine and very rapid basis." No individual or team can process that volume manually.
AI-assisted analysis is what makes large-scale signal processing feasible. Daley was direct: "This isn't something you can just go out to ChatGPT or Gemini and say, 'tell me what drug shortage is coming.' There are too many nuances involved." The right AI application here is one purpose-built for pharmaceutical supply chain data, capable of normalizing disparate datasets, filtering noise and surfacing actionable signals with validated confidence levels.
Actionable outputs close the loop. When a signal is detected, a predictive system doesn't just present data. It presents options. Which equivalent NDCs are available? Which vendors have stock? What's the predicted resolution timeline? These are the questions a pharmacy team needs answered at the point of decision, not buried in a data export.
Here's what makes drug shortage prediction genuinely difficult: the data needed to forecast shortages exists, but it's fragmented, siloed and largely treated as confidential by the manufacturers who hold it.
Daley's analysis of 22 published studies and policy recommendations points to a consistent theme. The most frequently cited improvement is greater transparency into where drugs are manufactured, where inventory sits and what the true supply picture looks like across the distribution network. That transparency doesn't exist systemically. It likely won't for years.
In the absence of that transparency, pharmacy-level tools that aggregate and analyze the data that is available become essential infrastructure. The pharmacies that get ahead of shortages are those that build the best intelligence picture from what they can access: vendor networks, wholesaler feeds, regulatory data and anonymized purchasing patterns across peer organizations.
How Predictive Pharmacy Intelligence Changes Each Care Setting
Every care setting faces shortages differently. The lead time that predictive intelligence provides plays out differently depending on the clinical context.
For community pharmacies, the patient relationship is the asset. When a patient arrives for a medication and is turned away, the risk isn't just one lost prescription. It's a potentially permanent loss of trust. Predictive tools allow retail pharmacists to identify equivalent NDCs and alternative vendors before the shelf goes empty.
Speed of response is directly tied to patient retention. The faster a pharmacy can pivot to an equivalent product, the more likely the patient is to stay and to return.
LTC residents depend on chronic therapy continuity in ways that make even brief supply disruptions clinically significant. Many are on complex, multi-drug regimens where a substitution requires prescriber involvement, care team coordination and family communication.
Predictive intelligence gives LTC pharmacy teams the lead time to initiate those conversations before a shortage forces them. A potential crisis becomes a managed transition instead.
The stakes in health system settings are amplified by the nature of the drugs most at risk. Generic sterile injectables, anesthetics, vasopressors and chemotherapy agents are among the most shortage-prone products and among the most critical to hospital operations.
Surgical programs are often the health system's primary revenue driver. An inability to source propofol, rocuronium or lidocaine can mean canceled procedures and direct financial loss. Health systems that implement predictive shortage management gain the ability to risk-stratify their formulary, identify which products carry the highest shortage risk and build clinical protocols and substitution pathways well in advance.
The difference between building those plans two months ahead versus the day a shortage hits is the difference between control and chaos.
Predictive tools are necessary but not sufficient on their own. What separates pharmacies that benefit from shortage intelligence from those that don't is whether the technology is paired with a formal response framework.
Daley's resilience framework, drawn from the National Academies of Sciences, Engineering, and Medicine, organizes shortage response activities around a foundation of communication, analytics and transparency. The key insight is that analytics isn't a support function. It's the base layer on which everything else depends.
In practice, resilient pharmacy teams do a few things in advance:
The goal isn't to eliminate shortages, which would require systemic manufacturing and supply chain reform beyond any single organization's control. The goal is to flatten the curve. To reduce the disruption that any given shortage causes to patients and operations by having a plan already in motion when it arrives.
Pharmacy teams have never been short on commitment to patient care. What's changed is the complexity of the environment they're operating in and the tools now available to help them stay ahead of it.
Drug shortage prediction at scale, with confidence levels validated over time, wasn't operationally feasible for most pharmacies even a few years ago. It is now. As the shortage environment continues to be shaped by global supply chain fragility, pricing pressure, geopolitical disruption and concentrated manufacturing, predictive intelligence is moving from a competitive advantage to a baseline expectation.
Leaders who build predictive pharmacy intelligence into their operations today won't just be better prepared for the next shortage. They'll be redefining what it means to run a pharmacy that patients, prescribers and health systems can actually depend on.
As Daley put it: "We are finally on the precipice of the future of dealing with drug shortages. We have the tools to be able to take all of this data, analyze it, ingest it and build workable actionable plans to help us be better at not only managing a shortage when it happens, but predicting when they're about to happen."
The future is here. The question is whether your pharmacy is ready for it.
See how SureCost Drug Shortage Insights™ gives your team predictive risk scores, alternative NDC recommendations and daily data refreshes, all within your existing purchasing workflow.
Sources